An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study was an extension study of NCT00537082. This study was designed to evaluate the
efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720)
to relapsing multiple sclerosis.